StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT) Following Mgmt. Meeting
August 7, 2025 11:05 AM
BMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $50.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Sarepta Therapeutics (SRPT) PT Raised to $50 at Wells Fargo
August 7, 2025 5:47 AM
Form 4 Sarepta Therapeutics, For: Aug 05 Filed by: Arif Bilal
August 6, 2025 8:03 PM
Form 4 Sarepta Therapeutics, For: Aug 05 Filed by: Estepan Ian Michael
August 6, 2025 8:02 PM
Form 4 Sarepta Therapeutics, For: Aug 05 Filed by: Rodino-Klapac Louise
August 6, 2025 8:01 PM
Sarepta Therapeutics (SRPT) Tops Q2 EPS by $1.32
August 6, 2025 4:19 PM
Form S-8 Sarepta Therapeutics,
August 6, 2025 4:17 PM
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
August 6, 2025 4:06 PM
Form 10-Q Sarepta Therapeutics, For: Jun 30
August 6, 2025 4:03 PM
Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending - Hagens Berman
August 5, 2025 6:29 PM
